FPA Patent Attorneys’ Post

Now that the U.S. patent officials have weighed in on AI inventorship, health innovators want to know: What does it all mean for cutting-edge drug discovery? 🤔 Join Fenwick partners Antonia Sequeira, Hayan Yoon, and associates Pinar Erciyas Bailey, Malashaan Kind, and Fredrick Tsang as they unpack what’s changed, examine successful patent strategies, and identify potential pitfalls for AI-assisted drug R&D. 👉 Register now: https://bit.ly/4a4F2qS What are your burning questions about patents and AI-assisted drug discovery? #LifeSciences #ArtificialIntelligence #Patents

Luke Tregilgas, Associate at Haley Guiliano LLP discussed how AI patentability in Europe could inform risk management discussions for investment in digital technology innovation within pharma - from the unique patent considerations for pharma/biotech patents and AI patents in Europe, to the potential effects of cross-over tech on patent grant rate, and the potential future implications of AI on patentability in Europe. #LSPNFall #Patents #IntellectualProperty

🧩 With new patent guidelines in place, you might be wondering what role AI can play in drug discovery🔬 It’s an issue Fenwick partners Antonia Sequeira, Hayan Yoon, and associates Pinar Erciyas Bailey, Malashaan Kind, and Fredrick Tsang are diving into head-first. Attend their upcoming webinar to learn: ⚡What is—and isn’t—covered under new U.S. patent guidelines ⚡Strategies and potential pitfalls in AI-assisted drug discovery ⚡Precautions to maximize patent coverage Register here: https://bit.ly/4a4F2qS How have you approached your AI-assisted drug discovery? #LifeSciences #ArtificialIntelligence #Patents

How do we address Eroom's law (https://lnkd.in/gyqMXr4M.) in drug discovery? Read ReSync Bio's take on addressing the grand challenge here: https://lnkd.in/gBB5Z8Jt

The USPTO uses an automated computer program to calculate patent expiration dates, which is subject to errors. In a new analysis, S. Sean Tu, Dinis Cheian, Sarah Gabriele, Benjamin Rome, and Aaron S. Kesselheim, M.D., J.D., M.P.H. reviewed the most recent 200 key drug patents to determine the number of errors and the potential revenues associated with the erroneously extended patent term. They find a 4% error rate in the automated program that could result in hundreds of millions of dollars in added costs. https://lnkd.in/eUM4KHay

Thank you Program on Regulation, Therapeutics, and Law (PORTAL) for covering our new paper on how USPTO's errors in computing patent terms lead to increased drug prices! This paper is a follow up to my earlier article in Fordham Intellectual Property, Media & Entertainment Law Journal: "I See Dead Patents: How Bugs in the Patent System Keep Expired Patents Alive" https://lnkd.in/e3TuNFEi

From clinical trials to launch, Corval delivers actionable commercialization plans faster than ever. Corval’s proprietary algorithm ensures your commercialization plans evolve seamlessly as your timelines, needs, or data change. https://hubs.la/Q02KcN4s0

AtlasGEN Novel Drug Designer significantly reduces the time and cost associated with other computational #drugdiscovery approaches, while compressing the hit-to-lead refinement and optimization process. Interested in learning more? Download the white paper: https://hubs.li/Q02DMkTK0

On Market Insight in August, Surendra Sharma of Remfry & Sagar reveals that a new code of conduct that regulates IP practitioners could be on the cards in India. In China, Miranda Xie of WANHUIDA INTELLECTUAL PROPERTY outlines how to patent targeted therapy pharmaceuticals, while Guan Yue analyses the Supreme People’s Court’s decision to invalidate two of Sanofi’s patents related to tablets to treat multiple sclerosis. Elsewhere, Lydia Bakalova, Bruce Rubinger and Tanner Knabe of Global Prior Art dive into the key players in the global surgical robotics landscape, while Nigel Swycher of LexisNexis Intellectual Property Solutions stresses the importance of data quality and how to avoid disillusionment when it comes to the role of AI in patent analytics. https://lnkd.in/gY884gyc #IP #AI #patents #pharma

https://lnkd.in/dPZZgNug This review describes the synthetic approach demonstrated on largest scale for each new drug based on patent or primary literature.